Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTMX returned -1.13%, Advisor Class fund APDMX posted a return of -1.12%, and Institutional Class fund APHMX returned -1.07%, compared to a return of 6.90% for the Russell Midcap Growth Index. In addition, please check the fund’s top five holdings to know its best picks in 2022.
Artisan Partners highlighted stocks like Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the Q4 2022 investor letter. Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharma technology company. On January 19, 2023, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $51.32 per share. One-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was -10.73%, and its shares gained 51.43% of their value over the last 52 weeks. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $6.939 billion.
Artisan Partners made the following comment about Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Q4 2022 investor letter:
“Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology firm with a unique technology platform enabling the conversion of intravenous (IV) formulated biologic and small molecule drugs to a subcutaneous (SC) formulation. Pharmaceutical companies license this technology to optimize their valuable therapies, generating predictable and durable royalties for Halozyme. The company has a robust pipeline of 16 products and over 10 companies leveraging its ENHANZE® platform, including a partnership with Argenx (another portfolio holding) for a subcutaneous format of efgartigimod, which could obtain approval in 2023. Today, Halozyme receives royalties on commercial sales of five products. Over the next five years, we believe its base of royalty-generating products could triple.”
Pressmaster/Shutterstock.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the third quarter which was 21 in the previous quarter.
We discussed Halozyme Therapeutics, Inc. (NASDAQ:HALO) in another article and shared the list of best diabetes stocks to buy. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- Dividend Aristocrats Ranked: Top 15
- 11 Best Debt Free Stocks To Buy
- 14 Best Dividend Stocks To Buy and Hold
Disclosure: None. This article is originally published at Insider Monkey.
